ANKE BIO(300009)2023-04-27 16:00Financial Performance - The company's operating revenue for Q1 2023 was CNY 594,174,209.84, representing a year-on-year increase of 11.40% compared to CNY 533,355,253.62 in the same period last year[27]. - The net profit attributable to shareholders of the listed company for Q1 2023 was CNY 185,618,139.71, reflecting a year-on-year growth of 7.36% from CNY 172,897,830.23[27]. - The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was CNY 178,156,883.51, up 12.68% from CNY 158,108,566.09 in the previous year[27]. - The net cash flow from operating activities increased by 31.35% to CNY 215,982,444.58, compared to CNY 164,433,196.39 in the same period last year[27]. - The company's total assets at the end of the reporting period were CNY 4,480,329,008.05, a 5.29% increase from CNY 4,255,325,817.63 at the end of the previous year[27]. - Total operating revenue for Q1 2023 reached ¥594,174,209.84, an increase of 11.43% compared to ¥533,355,253.62 in Q1 2022[38]. - Net profit for Q1 2023 was ¥188,850,882.44, representing a growth of 6.66% from ¥176,960,698.62 in Q1 2022[39]. - The total equity attributable to shareholders of the parent company increased to ¥3,419,565,300.37, compared to ¥3,208,622,822.65 in the previous year, reflecting a growth of 6.55%[38]. - The total assets as of Q1 2023 were ¥4,480,329,008.05, an increase from ¥4,255,325,817.63 in Q1 2022[38]. - The total liabilities as of Q1 2023 were ¥858,070,682.60, slightly up from ¥853,615,750.74 in Q1 2022[38]. Research and Development - The company's R&D investment has increased, contributing to the continuous progress of R&D projects, which supports high-quality development[28]. - The company's R&D expenses increased to ¥35,377,092.33, a rise of 22.06% compared to ¥28,996,807.93 in the same period last year[39]. - Research and development expenses for the period amounted to ¥35,377,100, representing a 22.0% increase compared to the previous year[43]. Shareholder Information - Total number of common shareholders at the end of the reporting period was 65,387[32]. - The largest shareholder, Song Lihua, holds 26.55% of shares, totaling 444,278,710 shares[32]. - The largest shareholder, Song Liming, holds 6.87% of shares, totaling 114,889,420 shares[32]. - The company is unaware of any other relationships or concerted actions among the top 10 shareholders, except for the relationship between Song Lihua and Song Liming[33]. Cash Flow and Liquidity - The company's cash and cash equivalents increased to ¥373,617,457.87 from ¥324,586,628.66 at the beginning of the year, a growth of approximately 15.5%[37]. - The cash and cash equivalents at the end of the period increased to ¥373,216,910.33 from ¥207,474,291.92, marking a significant improvement in liquidity[41]. - The net cash flow from investment activities was negative at -¥173,330,460.50, an improvement from -¥294,123,232.06 in the previous year, reflecting a 41.07% increase in cash flow from investments[47]. - In Q1 2023, the company's operating cash inflow totaled ¥558,257,243.14, an increase from ¥530,877,155.94 in the previous year, reflecting a growth of approximately 5.5%[41]. Operating Costs and Expenses - Total operating costs amounted to ¥377,413,240.03, up 10.52% from ¥341,436,111.47 in the previous year[39]. - The company's management expenses increased by 36.27% year-on-year, mainly due to the amortization of equity incentive expenses related to the restricted stock incentive plan[29]. - The company reported a decrease in sales expenses to ¥149,534,885.84, down 13.73% from ¥173,371,294.63 in Q1 2022[39]. - The company's tax expenses for Q1 2023 were ¥31,012,990.63, up from ¥27,592,749.01 in the same period last year[39]. Other Income and Investment - Other income decreased by 70.88% year-on-year, primarily due to a significant amount of government subsidies received in the same period last year[3]. - The company's investment income for Q1 2023 decreased by 82.46% year-on-year, attributed to significant changes in the investment income recognized from long-term equity investments[22]. - The company’s investment income for Q1 2023 was ¥431,079.56, a decrease from ¥2,458,005.94 in the previous year[39]. - The fair value change income decreased by 73.75% year-over-year, primarily due to the recovery of financial products that had significant fair value adjustments in the previous year[46]. Shareholder Equity and Restricted Shares - The total number of restricted shares at the beginning of the period was 513,769,070, with 2,693,000 shares released during the period, resulting in an ending balance of 511,494,801 shares[50]. - The company has a total of 34,792,400 shares under the third phase of the restricted stock incentive plan, which has completed registration and will be executed according to the relevant regulations[50]. - The number of shares held by key executives includes 325,934,032 shares for Song Lihua, with 2,425,000 shares released during the period[49]. - The company reported that 383,631 shares were added to Wang Yong's holdings during the reporting period, as he was elected as a supervisor[50]. - The total number of shares held by Zhao Hui decreased from 7,527,375 to 7,478,375 after releasing 49,000 shares[49]. - The company has a policy that allows executives to release 25% of their shares at the end of the previous year during their tenure[49]. - The total number of shares held by Liu Chunyan increased to 140,400 after adding 35,100 shares during the reporting period[50]. - The company has implemented a six-month lock-up period for shares held by executives after their term ends[49]. - The total number of shares held by Li Kun is 129,565, with no shares released during the period[50]. - The company continues to adhere to the regulations regarding the release of restricted shares for executives, ensuring compliance with corporate governance standards[49].